For pharmaceutical manufacturers and healthcare providers, non-adherence to medication is a significant concern.
Adare Pharmaceuticals transforms medicines, creating new possibilities for improved patient health.
For decades, the company has successfully overcome complex formulation challenges in specialized and diverse therapeutic categories such as cardiovascular, pain management, gastrointestinal (GI) and central nervous system (CNS), delivering medicines that benefit patients.
Using proprietary technologies, including taste masking and orally disintegrating tablets (ODT), customized drug release, and bioavailability enhancement, Adare has demonstrated the unique ability to transform drug formulations and create novel Rx and over-the-counter (OTC) products.
In addition, Adare can add valuable IP to commercialized products and products in development for business partners worldwide. With global research and development (R&D) and manufacturing facilities, Adare brings complex products from development to commercialization.
Since 2009, Adare’s partnerships have resulted in more than 60 product launches in 44 countries.
Taste masking technology platform
Adare offers proprietary technologies that provide taste masked products with a pleasant taste and excellent mouth-feel for patient appeal. These technologies include AdvaTab®, Liquitard®, and Microcaps®.
Customized drug release technology platform
The customized drug release technology platform consists of various technologies that provide a range of customized release profiles. These drug release profiles can be tailored to optimize a drug’s therapeutic performance by improving efficacy and enhancing safety.
Patient acceptability and compliance can be increased through less frequent dosing. Adare’s proprietary customized drug release technologies include Diffucaps®, Eurand Minitabs®, and Diffutab®.
Bioavailability enhancement technology platform
Adare provides technologies to enable and improve the bioavailability of drugs with low solubility or an extreme pH-dependent solubility profile.
The resulting formulations can offer effective oral dosing of poorly soluble drug candidates, equivalent therapy at lower doses, faster onset of action, and minimization of food effect. The bioavailability enhancement technologies provided by Adare include Biorise™ and Diffucaps® (solid solution or solid dispersion).
Collaborations and clients
The company meets its partners’ business needs by offering technologies and resources for the development of new product formulations or licensing availability of existing product formulations (both Rx and OTC.)
Adare’s partnership process provides its clients with an experienced management team across all functions and stages of the product development cycle.
Adare has a multinational infrastructure and integrated R&D and manufacturing facilities in the US and Europe, thereby delivering global solutions to companies in various regions worldwide.
The company’s global business development and licensing teams aim to provide flexible deal structures to help maximize its partners’ interests.
In July 2016, US-based innovative life sciences company Cambrex Corporation completed a major expansion of its active pharmaceutical ingredient (API) facility in Charles City, Iowa.
Adare Pharmaceuticals has officially opened a new corporate headquarters at 1200 Lenox Drive in Lawrenceville, New Jersey.
Global specialty pharmaceutical company Adare Pharmaceuticals will present its company overview at the BIO International Convention in California.
Sanofi K.K has announced that Allegra dry syrup 5% has launched in Japan.
Aptalis has signed a definitive agreement to be acquired by Forest Laboratories, a leading, fully integrated, specialty pharmaceutical company, for $2.9bn in cash pending required reviews.
Aptalis Pharmaceutical Technologies Co-Sponsors 2013 Controlled Release Society’s Young Investigator Award at 40th Annual Meeting and Exposition
Aptalis Pharmaceutical Technologies, a business unit of Aptalis Pharma that focuses on developing patient-optimised oral products utilising its proprietary pharmaceutical technologies and development expertise, hasa announced its co-sponsorship of Controlled Release Society's Young Investigator Award.
Aptalis Pharmaceutical Technologies, a business unit of Aptalis Pharma that develops differentiated products utilizing its oral delivery technologies, today announces that Nigel Ray has been named as the company's Vice President of Global Licensing.
Aptalis Pharmaceutical Technologies has released two free white papers on Pharmaceutical Technology.
Aptalis Pharmaceutical Technologies, formerly Eurand Pharmaceutical Technologies, focused on developing differentiated oral products utilising its pharmaceutical technologies, today announced that the European Commission has granted marketing authorisation for a new pediatric indication of a new oral granule formulation of Gilead Sciences's Viread® (tenofovir disoproxil fumarate) for HIV-1 infected children aged two to six years of age, and for HIV-1 infected children above six years of age for whom a solid dosage form is not appropriate.
FDA approvals, revenue gain and organic business growth are just a few of the topics that Aptalis Pharma president John Fraher addresses during an on-air interview with PharmaVentures and PharmaTelevision CEO Fintan Walton. The interview, conducted during BIO 2012 in Boston, reflects Fraher's commentary regarding the integration of companies post Axcan Intermediate Holdings' acquisition of Eurand NV in 2011.
Aptalis Pharmaceutical Technologies Sponsors 2012 Controlled Release Society’s Young Investigator Award
Aptalis Pharmaceutical Technologies has announced its co-sponsorship of the Controlled Release Society's Young Investigator Award and its participation in the 39th Annual Meeting & Exposition of the Controlled Release Society.
Aptalis Pharmaceutical Technologies has released two new free-to-download white papers on Pharmaceutical Technology.
Aptalis (previously known as Eurand, Inc.), Cephalon, a wholly-owned subsidiary of Teva Pharmaceuticals Industries Ltd, and Anesta AG prevailed in their appeal to the U.S. Court of Appeals for the Federal Circuit, which reversed a lower court's determination and held that two patents covering the AMRIX muscle relaxant (Cyclobenzaprine Hydrochloride Extended-Release Capsules) are valid.
Aptalis Pharma Announces FDA Approval of NDA for Oral Powder Formulation of Viread®, Co-Developed with Gilead Sciences
Aptalis Pharma has announced that the US Food and Drug Administration (FDA) has approved a new drug application (NDA) for Gilead Sciences' Viread® (tenofovir disoproxil fumarate) oral powder in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients ages 2-5.
Company strategy, portfolio development and emerging markets are just a few of the topics that John Fraher, president of Aptalis Pharma, is scheduled to address during an on-air interview with Fintan Walton, CEO, PharmaVentures and PharmaTelevision. The interview is available via on-demand at Pha
Aptalis Pharmaceutical Technologies to Host Webinar: Competitive Advantages of Intelligent Formulation Design
At a time when difficult to formulate molecules and a decline of new chemical entities (NCEs) for new therapies have resulted in pipeline gaps, weakened product portfolios and a challenging R&D environment, the need to create products that address unmet medical needs and marketable advantages
Steve Ellul, Eurand's director of licensing, will discuss aspects of the company's growth strategy during the session 'Understanding the Drivers for Strategic Decision-Making' at BioEurope Spring in Milan, Italy, on Monday 14 March from 9am to 10.30am local time. The panel of industry
Eurand, a global specialty pharmaceutical company, and Nycomed, a privately owned global pharmaceutical company, have announced an exclusive commercialization, license and supply agreement for Russia and the Commonwealth of Independent States (CIS), as well as Georgia and Mongolia. Financial term
Eurand, a global specialty pharmaceutical company, has conducted a webinar titled 'The $10 Billion Gap: Leveraging Taste-Masking Technologies to Meet Global Patient Needs', presented by Troy Harmon, vice president of business development, and Andrew Thompson, vice president of commercial operatio
Eurand, a global specialty pharmaceutical company, today reported revenues for the second quarter of 2010 of €32.9m ($40.5m), an increase of 8%, or 3% in constant currency, from the second quarter of 2009. For the six months ended 30 June 2010, revenues totaled €64m ($78.7m), up
Eurand Announces Data on Switching Cystic Fibrosis Patients With Exocrine Pancreatic Insufficiency to FDA-Approved ZENPEP
Eurand Pharmaceuticals, a subsidiary of global specialty pharmaceutical company Eurand, today announced additional data from a post-hoc analysis of a Phase III clinical trial with ZENPEP® (pancrelipase) delayed-release capsules, an FDA-approved pancreatic enzyme product (PEP) for the treatme
Eurand, a global specialty pharmaceutical company, today announced the appointment of Jean-Louis Anspach as president, Eurand Pharmaceuticals, Inc. (EPI). Anspach is a 25-year veteran of the specialty pharmaceutical and chemical industries and was most recently executive vice president, marketing
Eurand, a global specialty pharmaceutical company, announced today the grant of US Patent No. 7,658,918, titled 'Stable digestive enzyme compositions', by the United States Patent and Trademark Office (USPTO). The patent will provide Eurand with coverage until at least 20 February 2028 on ZENPEP&
Eurand Successfully Completes Registration Procedure for Paracetamol ODT 250mg and 500mg in the European Union
Eurand, a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, announced today that the Dutch Medicines Evaluation Board (MEB) informed the company that the decentralized procedure (DCP) for reg
Eurand, a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, today announced that the US Food and Drug Administration (FDA) has approved EUR-1048, to be marketed as GlaxoSmithKline's Lamictal&
Eurand Initiates the Second of Two Phase III Studies for EUR-1008 In Patients With Pancreatic Insufficiency
Eurand, a specialty pharmaceutical company, today announced the initiation of the second of two Phase III clinical trials required for registration of its Pancreatic Enzyme Product (PEP), EUR-1008, in patients with Exocrine Pancreatic Insufficiency (EPI). EPI is a deficiency of digestive enzymes
Via Martin Luther King, 13
20060, Pessano con Bornago
845 Center Drive
United States of America